Validation Study of Ventana SP263 PD-L1 Immunohistochemistry Antibody Assay as LDT for Clinical Use in patients with NSCLC being considered for Keytruda Therapy-MedSci.cn

Validation Study of Ventana SP263 PD-L1 Immunohistochemistry Antibody Assay as LDT for Clinical Use in patients with NSCLC being considered for Keytruda Therapy

Marolt, M; Racila, E

MODERN PATHOLOGY, 2019; 32 ():

科室
- - 订阅+
  - 更多科室
工具
服务